1. Introduction {#sec1-ijerph-17-05694}
===============

Lung cancer has the highest global incidence and mortality rate of all cancers \[[@B1-ijerph-17-05694]\]. According to statistical data from Taiwan's Ministry of Health and Welfare, the leading causes of cancer-related death in 2018 were tracheal, bronchial, and lung cancer. Lung adenocarcinoma, accounting for approximately 50% of lung cancer cases, occurs frequently in the female and nonsmoking populations \[[@B2-ijerph-17-05694],[@B3-ijerph-17-05694]\]. In addition to environmental risk factors such as smoking and exposure to certain chemicals, genetic variation also increases the risk of lung cancer. Up to 30% of patients with lung adenocarcinoma in the Asian population have been shown to harbor epidermal growth factor receptor (*EGFR*) mutations \[[@B4-ijerph-17-05694],[@B5-ijerph-17-05694]\]. Although *EGFR* inhibitors are highly efficacious in treating lung cancer, not all lung adenocarcinomas respond to this therapy. Therefore, the identification of other biomarkers and novel treatment strategies for lung adenocarcinoma is an unmet need.

Fibroblast growth factor receptors (*FGFR*s), which comprise five members (*FGFR1*-5), belong to the receptor tyrosine kinase family \[[@B6-ijerph-17-05694]\]. *FGFR*s participate in multiple physiological and pathological processes, such as proliferation, differentiation, metabolism, and migration \[[@B6-ijerph-17-05694]\]. Dysregulation of *FGFR* signaling cascades has been shown to be highly associated with tumor development in numerous human cancers \[[@B7-ijerph-17-05694]\]. Single-nucleotide polymorphisms (SNPs), the most common type of genetic variation, are reported to be significantly associated with cancer morbidity and mortality \[[@B8-ijerph-17-05694]\]. Numerous SNPs in *FGFR* genes, including *FGFR4*, have been identified as being significantly associated with cancer susceptibility and progression \[[@B7-ijerph-17-05694],[@B9-ijerph-17-05694]\]. The human *FGFR4* gene is located on chromosomal locus 5q35 and contains 18 exons \[[@B10-ijerph-17-05694]\]. Recent studies have focused on the clinical significance of *FGFR4* genetic variations \[[@B10-ijerph-17-05694]\]. *FGFR4* SNPs have been shown to be significantly associated with poor survival rates and worse prognosis in prostate cancer \[[@B11-ijerph-17-05694],[@B12-ijerph-17-05694]\], head and neck cancer \[[@B13-ijerph-17-05694],[@B14-ijerph-17-05694]\], breast cancer \[[@B15-ijerph-17-05694],[@B16-ijerph-17-05694],[@B17-ijerph-17-05694],[@B18-ijerph-17-05694],[@B19-ijerph-17-05694]\], ovarian cancer \[[@B20-ijerph-17-05694]\], hepatocellular carcinoma \[[@B21-ijerph-17-05694]\], uterine cervical cancer \[[@B22-ijerph-17-05694]\], urothelial cell carcinoma \[[@B23-ijerph-17-05694]\], pituitary tumors \[[@B24-ijerph-17-05694],[@B25-ijerph-17-05694]\], soft tissue sarcoma \[[@B26-ijerph-17-05694]\], and oral squamous cell carcinoma \[[@B27-ijerph-17-05694],[@B28-ijerph-17-05694],[@B29-ijerph-17-05694]\]. However, the effects of *FGFR4* SNPs on the risk of lung cancer seem to be controversial. The most common *FGFR4* genetic variant in lung cancer is the SNP rs351855 G/A, which is in the exon 9 coding region of the *FGFR4* gene. The *FGFR4* SNP rs351855 induces the substitution of glycine for arginine at codon 388 (G388R) in the transmembrane domain of the FGFR4 protein receptor \[[@B30-ijerph-17-05694],[@B31-ijerph-17-05694]\]. The FGFR4-G388R SNP has been shown to be significantly correlated with poor outcomes, including lymph node involvement and reduced overall survival \[[@B32-ijerph-17-05694],[@B33-ijerph-17-05694]\], and is associated with worse survival in node-positive patients \[[@B34-ijerph-17-05694]\]. Conversely, this SNP was also reportedly correlated with better outcomes, including longer overall survival and reduced cancer risk in patients with non-small-cell lung carcinoma \[[@B35-ijerph-17-05694]\]. In addition, no association between *FGFR4* variants and clinical outcomes has been found \[[@B36-ijerph-17-05694]\]. These conflicting results require further examination using a greater variety of research designs.

The role of *FGFR4* gene polymorphisms in the clinicopathological characteristics of lung adenocarcinoma in the Taiwanese cohort remains unclear. The prevalence of *EGFR* mutations is relatively high in the Taiwanese population with lung adenocarcinoma \[[@B2-ijerph-17-05694],[@B4-ijerph-17-05694]\]. Therefore, we examined the association between the *FGFR4* SNPs and *EGFR* mutation in Taiwanese patients with lung adenocarcinoma. We explored four SNPs of *FGFR4*, namely rs2011077, rs351855, rs7708357, and rs1966265, to examine the pathophysiological effects on tumorigenesis of several cancers. Furthermore, we studied the effect of *FGFR4* SNPs on the clinicopathological characteristics of lung adenocarcinoma with and without *EGFR* mutation.

2. Materials and Methods {#sec2-ijerph-17-05694}
========================

2.1. Participant Selection and Specimen Collection {#sec2dot1-ijerph-17-05694}
--------------------------------------------------

This study included 277 patients with lung adenocarcinoma at Cheng-Ching General Hospital in Taichung, Taiwan between 2012 and 2015. Each patient provided signed informed consent before initiation of the study. From all participants, tumor tissue specimens and whole-blood specimens were collected for *EGFR* gene sequencing and *FGFR4* gene polymorphism analysis, respectively. The clinical information of the enrolled patients and the examined lifestyle variables (e.g., cigarette smoking) were obtained from medical records and questionnaires, respectively. The adenocarcinoma was staged in accordance with the TNM Classification of Malignant Tumors (where TNM refers to tumor/node/metastasis) of the American Joint Committee on Cancer, where T1--T4 describes primary tumor sizes and the invasion of adjacent tissues, N describes the regional lymph nodes involved, and M describes distant metastasis \[[@B37-ijerph-17-05694]\]. The study protocol was approved by the Institutional Review Board of Cheng-Ching General Hospital (No. HP120009; 22 September 2012).

2.2. Genomic DNA Extraction and EGFR Gene Sequencing {#sec2dot2-ijerph-17-05694}
----------------------------------------------------

Genomic DNA from tumor tissues and whole-blood specimens of patients with lung adenocarcinoma were prepared as described previously \[[@B38-ijerph-17-05694]\]. DNA was extracted using the QIAamp Fast DNA Tissue Kit and the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. DNA from the tumor tissues was used as a template. Exons 18--21 of the EGFR gene were amplified using the polymerase chain reaction (PCR) and then subjected to the DNA sequencing reaction using the ABI PRISM 3130XL System (Applied Biosystems, Foster City, CA, USA) as described previously \[[@B3-ijerph-17-05694]\].

2.3. Genotyping of FGFR4 Polymorphisms {#sec2dot3-ijerph-17-05694}
--------------------------------------

The four SNPs investigated, namely rs2011077, rs351855, rs7708357, and rs1966265, in the *FGFR4* genome region have been well defined and suggested to be associated with the risk of various cancers susceptibility \[[@B22-ijerph-17-05694],[@B23-ijerph-17-05694],[@B29-ijerph-17-05694],[@B39-ijerph-17-05694]\]. The peripheral blood samples from lung cancer patients were collected for genomic DNA extraction. The whole blood samples were placed in EDTA containing tubes and were centrifuged at 3000 rpm, for 10 min as described previously \[[@B40-ijerph-17-05694]\]. Real-time PCR genotyping with the TaqMan SNP Genotyping Assay and the ABI StepOne Real-Time PCR System were used to examine the SNPs (Applied Biosystems, Foster City, CA, USA).

2.4. Statistical Analysis {#sec2dot4-ijerph-17-05694}
-------------------------

Differences in the distributions of clinical characteristics and genotype frequencies between patients with lung adenocarcinoma harboring wild-type *EGFR* and mutant-type *EGFR* were analyzed using the Mann--Whitney U test and Fisher's exact test. The association between the genotype frequencies and risk of *EGFR* types was estimated using multiple logistic regression models after controlling for other variables and is presented as odds ratios (ORs) with corresponding 95% confidence intervals (CIs). A *p*-value of \<0.05 was considered to be statistically significant. All analyses were generated using SAS software, version 9.1 of the SAS System (SAS Institute Inc., Cary, NC, USA).

3. Results {#sec3-ijerph-17-05694}
==========

3.1. Characteristics of the Study Population {#sec3dot1-ijerph-17-05694}
--------------------------------------------

A total of 277 patients with lung adenocarcinoma, divided into those harboring wild-type *EGFR* (*n* = 108, 40%) and those harboring mutant-type *EGFR* (*n* = 169, 60%) were included in this study. [Table 1](#ijerph-17-05694-t001){ref-type="table"} shows the clinical characteristics of the enrolled patients. As [Table 1](#ijerph-17-05694-t001){ref-type="table"} shows, the two groups, the wild-type *EGFR* group and the mutant-type *EGFR* group, differed significantly with respect to gender (*p* \< 0.001), cigarette smoking (*p* \< 0.001), and cell differentiation (*p* = 0.002). The *EGFR* mutant-type group had a higher proportion of women (*n* = 109, 64.5%), nonsmokers (*n* = 131, 77.5%), and cases of well differentiated (*n* = 21, 12.4%) and moderately differentiated tumors (*n* = 138, 81.7%) compared with the *EGFR* wild-type group ([Table 1](#ijerph-17-05694-t001){ref-type="table"}). The other clinicopathological characteristics, such as tumor stage, tumor T status, lymph node status, and distant metastasis, were similar between groups ([Table 1](#ijerph-17-05694-t001){ref-type="table"}).

3.2. Genotype Distributions of FGFR4 Polymorphisms in Patients with Lung Adenocarcinoma {#sec3dot2-ijerph-17-05694}
---------------------------------------------------------------------------------------

To explore the effects of *FGFR4* polymorphisms on lung adenocarcinoma risk, a whole-blood specimen from each of the 277 patients was collected and examined for genotype frequencies of the four *FGFR4* SNPs (rs2011077, rs351855, rs7708357, and rs1966265). The genotype distributions and associations between the four *FGFR4* polymorphisms and lung adenocarcinoma are shown in [Table 2](#ijerph-17-05694-t002){ref-type="table"}. Among the patients, the alleles with the highest distribution frequency for rs2011077, rs351855, rs7708357, and rs1966265 were heterozygous for T/C, heterozygous for G/A, homozygous for G/G, and heterozygous for A/G, respectively. To reduce the influence of possible confounding variables, we used adjusted ORs with 95% CIs---estimated using the multiple logistic regression model after normalizing for age, gender, and smoking habits---to evaluate the distribution of SNPs. As [Table 2](#ijerph-17-05694-t002){ref-type="table"} shows, no significant differences in the genotype distributions of the four *FGFR4* SNPs between patients with wild-type *EGFR* versus those with mutant-type *EGFR* lung adenocarcinoma were observed.

3.3. Associations between FGFR4 SNPs rs2011077 and rs351855 and Distant Metastasis among Lung Adenocarcinoma Patients with the Wild-Type EGFR Gene {#sec3dot3-ijerph-17-05694}
--------------------------------------------------------------------------------------------------------------------------------------------------

Next, we examined the genotype frequencies of each of the four *FGFR4* SNPs and the clinicopathological characteristics of the patients: Whole tumor stage, tumor T status (primary tumor size), lymph node status, existence of distant metastasis, and cell differentiation (the histopathological grading status). As [Table 3](#ijerph-17-05694-t003){ref-type="table"} shows, we observed an inverse association between *FGFR4* rs2011077 and distant metastasis, although it was not significant (*n* = 277, *p* = 0.061). We further performed a subgroup analysis based on the EGFR status: Wild-type (*n* = 108) and mutant-type (*n* = 169). Compared with the homozygous TT genotype, the existence of at least one allele of SNP rs2011077 C genotype (TC and CC) was associated with a significantly lower risk of distant metastasis (OR: 0.348, 95% CI: 0.136--0.891, *p* = 0.024) in the patients harboring wild-type *EGFR* (*n* = 108; [Table 3](#ijerph-17-05694-t003){ref-type="table"}). Patients with the GG genotype were taken as a reference, and the existence of at least one carrier allele in FGFR4 rs351855 had a significantly reduced risk for distant metastasis in all patients (*n* = 277, OR = 0.523, 95% CI = 0.304--0.899, *p* = 0.018; [Table 4](#ijerph-17-05694-t004){ref-type="table"}). In the *EGFR* wild-type group, a significantly reduced presence of distant metastasis was also observed in patients with the *FGFR4* rs351855 A genotype (GA and AA) compared with those with GG homozygotes (*n* = 108, OR = 0.296, 95% CI = 0.116--0.751, *p* = 0.008; [Table 4](#ijerph-17-05694-t004){ref-type="table"}). In addition, no significant association was found between the other two FGFR4 polymorphisms and the clinicopathological characteristics (data not shown).

3.4. Clinical Relevance of FGFR4 Levels in Lung Adenocarcinoma Patients with the Wild-Type EGFR Gene Obtained from the Cancer Genome Atlas (TCGA) Databases {#sec3dot4-ijerph-17-05694}
-----------------------------------------------------------------------------------------------------------------------------------------------------------

Considering the potential effects of *FGFR4* expression levels in the clinicopathological characteristics in lung adenocarcinoma, we further analyzed the correlations between the *FGFR4* expression level and the survival rate in 492 lung adenocarcinoma patients from The Cancer Genome Atlas (TCGA) database. In the TCGA database, 380 patients were early stage (stage I + II). A total of 163 and 24 patients were lymph node metastasis (33.1%) and distant metastasis (4.88%), respectively. As shown in [Figure 1](#ijerph-17-05694-f001){ref-type="fig"}, we found that patients in wild-type *EGFR* lung adenocarcinoma with higher *FGFR4* expression had shorter overall survival times and five-years survival times compared with those with lower *FGFR4* expression (*p* = 0.008; [Figure 1](#ijerph-17-05694-f001){ref-type="fig"}A; *p* = 0.006; [Figure 1](#ijerph-17-05694-f001){ref-type="fig"}B). No significant differences in the *FGFR4* expression and survival rates were observed in all patients with lung adenocarcinoma and in lung adenocarcinoma patients with mutant-type *EGFR*. Therefore, the expression level of *FGFR4* may provide clinical significance for the survival rate of lung adenocarcinoma patients with wild-type *EGFR*.

4. Discussion {#sec4-ijerph-17-05694}
=============

In the present study, we found no significantly different frequencies of the *FGFR4* SNPs rs2011077, rs351855, rs7708357, and rs1966265 in patients with wild-type EGFR and mutant-type *EGFR* lung adenocarcinoma. The existence of at least one allele of the rs2011077 C genotype or the rs351855 A genotype was associated with a significantly reduced presence of distant metastasis in the *EGFR* wild-type group. The data indicate that both *FGFR4* SNPs rs2011077 and rs351855 may be associated with reduced presence of distant metastasis in Taiwanese patients with lung adenocarcinoma, especially those with the wild-type *EGFR* gene. *FGFR4* SNPs may help in identifying patient subgroups at low-risk for tumor metastasis, among carriers of lung adenocarcinoma bearing wild-type *EGFR*.

Previous studies have shown that the Asia-Pacific patients with lung adenocarcinoma had the higher *EGFR* mutation frequency (47% (5958/12819)) and the Oceania patients with lung adenocarcinoma showed the lower *EGFR* mutation frequency (12% (69/570)) \[[@B41-ijerph-17-05694]\]. *EGFR* mutations have been found to occur more frequently in the female and nonsmoking populations and mainly occur in patients with lung adenocarcinoma in the Asian population \[[@B4-ijerph-17-05694],[@B41-ijerph-17-05694],[@B42-ijerph-17-05694]\]. Hsu et al., reported that the *EGFR* mutation rate in Taiwan is higher than 50%, based on data from the National Taiwan Lung Cancer Registry \[[@B2-ijerph-17-05694]\]. Consistent with these findings, we noted a higher proportion of women, never-smokers, and cases of well or moderately differentiated tumors in the collected samples. Moreover, most of the specimens were positive for *EGFR* mutations. Two *EGFR* mutations, an in-frame deletion within exon 19 and the L858R point mutation in exon 22, account for approximately 90% of overall *EGFR* mutations in lung adenocarcinoma \[[@B43-ijerph-17-05694],[@B44-ijerph-17-05694]\]. We examined the exons 18--21 of the *EGFR* gene using direct sequencing to examine *EGFR* mutations in this study. Indeed, a high frequency of *EGFR* mutations (60%) was found in our cohort. No significant association between the four *FGFR4* SNPs and *EGFR* wild-type and *EGFR* mutant-type lung adenocarcinoma was found after adjustment for gender, cigarette smoking, and cell differentiation.

Increasing evidence indicates that upregulation of *FGFR4* expression levels participate in tumorigenesis and cancer progression; thus, *FGFR4* has been proven as a therapeutic target for several cancers \[[@B10-ijerph-17-05694]\]. Using in silico analysis of the TCGA database, we found that lung adenocarcinoma patients bearing wild-type *EGFR* with the higher *FGFR4* expression level is correlated with poor overall survival rates and five-years survival rates compared with those with lower *FGFR4* expression patients. The increased *FGFR4* expression is correlated with worse overall survival in head and neck squamous cell carcinoma \[[@B13-ijerph-17-05694]\]. Moreover, *FGFR4* rs351855 SNP is associated with the increased *FGFR4* protein expression and a worse prognosis \[[@B15-ijerph-17-05694]\]. However, the previous study has found that *FGFR4* mRNA expression levels are not associated with *FGFR4* genotypes in healthy lungs of lung cancer patients \[[@B32-ijerph-17-05694]\]. A further study is the association between various *FGFR4* SNPs and *FGFR4* expression levels in lung adenocarcinoma.

We observed that the *FGFR4* SNP rs2011077 T/C was significantly inversely associated with distant metastasis. In addition, after the patients were stratified by the *EGFR* status, both *FGFR4* SNPs rs2011077 T/C and rs351855 G/A were found to be inversely associated with distant metastasis. The *FGFR4* SNP rs351855 G/A, which causes a substitution of glycine for arginine at codon 388 (G388R), has been proven to be related to worse prognosis in many cancers. Fang et al. revealed that the *FGFR4* rs351855 A genotype is correlated with longer overall survival and reduced cancer risk in patients with Stage III (A + B) or IV non-small-cell lung carcinoma \[[@B35-ijerph-17-05694]\]. The meta-analytic evidence has demonstrated a modest reduction in the risk of lung cancer \[[@B30-ijerph-17-05694]\]. Moreover, no significant association between this *FGFR4* genetic variant and clinical outcomes was found \[[@B36-ijerph-17-05694]\]. By contrast, several studies have reported that patients carrying the *FGFR4* rs351855 A genotype had poorer outcomes, including lymph node involvement and reduced overall survival \[[@B32-ijerph-17-05694],[@B33-ijerph-17-05694],[@B34-ijerph-17-05694]\]. Using the molecular approach, the G388R substitution in *FGFR4* was found to cause a conformational change in the *FGFR4* receptor, which then recruits the signal transducer and activator of transcription 3 (STAT3) to the inner cell membrane. The evidence demonstrated that the rs351855 SNP is a significant risk for cancer prognosis and tumor progression \[[@B45-ijerph-17-05694]\]. Moreover, a study using *FGFR4* rs351855-A/A-knockin transgenic mice to investigate lung cancer observed a marked decrease in the number of tumor-infiltrating CD8-positive T cells and a significant increase in regulatory T cell proportions compared with those from the G/G-knockin mice \[[@B46-ijerph-17-05694]\]. These results suggest that *FGFR4* rs351855 alone could exhibit an immune evasive phenotype of the tumor microenvironment in lung cancer progression \[[@B46-ijerph-17-05694]\]. The fact that other studies have reached the opposite conclusion may be due to unknown causes other than *FGFR4* variants. The possibilities of other genetic variations and a greater variety of abnormal signaling molecules are worthy of further investigation.

5. Conclusions {#sec5-ijerph-17-05694}
==============

Our findings concerning *FGFR4* SNPs rs2011077 and rs351855 may suggest a lower risk of tumor distant metastasis and *FGFR4* gene expression levels may help the prediction of survival rates in Taiwanese lung adenocarcinoma patients, especially those bearing the wild-type *EGFR* gene. The potential mechanisms involved in dysregulated *FGFR4* signaling cascades in Taiwanese patients with lung adenocarcinoma, particularly those with the wild-type *EGFR* gene, warrant further exploration. Further large-scale prospective studies are required to verify the significance of *FGFR4* genetic polymorphisms in lung adenocarcinoma.
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ijerph-17-05694-t001_Table 1

###### 

Clinical characteristics in lung adenocarcinoma patients with the epidermal growth factor receptor (*EGFR*) wild-type or mutation-type.

  Subject Characteristics             Wild-Type (*n* = 108)   Mutation-Type (*n* = 169)   *p*-Value
  ----------------------------------- ----------------------- --------------------------- -----------
  **Age, *n* (%)**                                                                        
  Mean ± SD (years)                   65.52 ± 13.55           65.76 ± 13.57               0.817
  **Gender, *n* (%)**                                                                     
  Male                                65 (60.2%)              60 (35.5%)                  \<0.001
  Female                              43 (39.8%)              109 (64.5%)                 
  **Cigarette smoking, *n* (%)**                                                          
  Non-smoker                          48 (44.4%)              131 (77.5%)                 \<0.001
  Ever-smoker                         60 (55.6%)              38 (22.5%)                  
  **Stage, *n* (%)**                                                                      
  I + II                              26 (24.1%)              47 (27.8%)                  0.491
  III + IV                            82 (75.9%)              122 (72.2%)                 
  **Tumor T status, *n* (%)**                                                             
  T1 + T2                             60 (55.6%)              108 (63.9%)                 0.165
  T3 + T4                             48 (44.4%)              61 (36.1%)                  
  **Lymph node status, *n* (%)**                                                          
  Negative                            28 (25.9%)              54 (32.0%)                  0.284
  Positive                            80 (74.1%)              115 (68.0%)                 
  **Distant Metastasis, *n* (%)**                                                         
  Negative                            54 (50.0%)              80 (47.3%)                  0.665
  Positive                            54 (50.0%)              89 (52.7%)                  
  **Cell differentiation, *n* (%)**                                                       
  Well                                8 (7.4%)                21 (12.4%)                  0.002
  Moderately                          79 (73.1%)              138 (81.7%)                 
  Poorly                              21 (19.4%)              10 (5.9%)                   

Categorical data: *n* (%); continuous variables: Mean + standard deviation (SD); Mann-Whitney U test or Fisher's exact test was used to evaluate the comparisons between *EGFR* wild-type and mutation-type in lung adenocarcinoma patients. *p*-value \< 0.05 was defined as statistical significant.

ijerph-17-05694-t002_Table 2

###### 

Distribution frequency of fibroblast growth factor receptor 4 (*FGFR4*) genotypes of patients with lung adenocarcinoma and multiple logistic regression analysis of *EGFR* mutation association.

  Genotype SNP    Wild-Type (*n* = 108)   Mutation-Type (*n* = 169)   AOR (95% CI)        *p*-Value
  --------------- ----------------------- --------------------------- ------------------- -----------
  **rs2011077**                                                                           
  TT              26 (24.1%)              46 (27.2%)                  1.00                
  TC              58 (53.7%)              78 (46.2%)                  0.86 (0.46--1.60)   0.625
  CC              24 (22.2%)              45 (26.6%)                  1.16 (0.56--2.42)   0.684
  TC + CC         82 (75.9%)              123 (72.8%)                 0.95 (0.52--1.71)   0.858
  **rs351855**                                                                            
  GG              28 (25.9%)              48 (28.4%)                  1.00                
  GA              59 (54.6%)              80 (47.3%)                  0.95 (0.51--1.76)   0.870
  AA              21 (19.5%)              41 (24.3%)                  1.25 (0.59--2.63)   0.561
  GA + AA         80 (74.1%)              121 (71.6%)                 1.03 (0.58--1.85)   0.914
  **rs7708357**                                                                           
  GG              103 (95.4%)             165 (97.6%)                 1.00                
  GA              5 (4.6%)                3 (1.8%)                    0.52 (0.11--2.43)   0.402
  AA              0 (0.0%)                1 (0.6%)                                        
  GA + AA         5 (4.6%)                4 (2.4%)                    0.64 (0.15--2.67)   0.535
  **rs1966265**                                                                           
  AA              27 (25.0%)              44 (26.0%)                  1.00                
  AG              58 (53.7%)              82 (48.5%)                  0.97 (0.52--1.82)   0.935
  GG              23 (21.3%)              43 (25.5%)                  1.31 (0.62--2.74)   0.482
  AG + GG         81 (75.0%)              125 (74.0%)                 1.07 (0.59--1.93)   0.826

The AORs with 95% CIs were estimated by multiple logistic regression models after controlling for age and gender. Abbreviations: SNP: Single nucleotide polymorphism; AOR: Adjusted odds ratio; CI: Confidence interval.

ijerph-17-05694-t003_Table 3

###### 

Clinicopathologic characteristics of lung adenocarcinoma patients with *EGFR* mutation, stratified by polymorphic genotypes of *FGFR4* rs2011077.

  Variable                   ALL (*n* = 277)   *EGFR* Wild-Type (*n* = 108)   *EGFR* Mutation (*n* = 169)                                                                              
  -------------------------- ----------------- ------------------------------ ----------------------------- ------------ ------------ --------------------- ------------ ------------- -------------
  **Stages**                                                                                                                                                                           
  I+II                       19 (26.4%)        54 (26.3%)                     *p* = 0.994                   5 (19.2%)    21 (25.6%)   *p* = 0.507           14 (30.4%)   33 (26.8%)    *p* = 0.642
  III+IV                     53 (73.6%)        151 (73.7%)                                                  21 (80.8%)   61 (74.4%)                         32 (69.6%)   90 (73.2%)    
  **Tumor T status**                                                                                                                                                                   
  T1+T2                      40 (55.6%)        128 (62.4%)                    *p* = 0.304                   11 (42.3%)   49 (59.8%)   *p* = 0.119           29 (63.0%)   79 (64.2%)    *p* = 0.887
  T3+T4                      32 (44.4%)        77 (37.6%)                                                   15 (57.7%)   33 (40.2%)                         17 (37.0%)   44 (35.8%)    
  **Lymph node status**                                                                                                                                                                
  Negative                   23 (31.9%)        59 (28.8%)                     *p* = 0.613                   6 (23.1%)    22 (26.8%)   *p* = 0.704           17 (37.0%)   37 (30.1%)    *p* = 0.394
  Positive                   49 (68.1%)        146 (71.2%)                                                  20 (76.9%)   58 (73.2%)                         29 (63.0%)   86 (69.9%)    
  **Distant metastasis**                                                                                                                                                               
  Negative                   28 (38.9%)        106 (51.7%)                    *p* = 0.061                   8 (30.8%)    46 (56.1%)   ***p* = 0.024 ^a^**   20 (43.5%)   60 (48.8%)    *p* = 0.539
  Positive                   44 (61.1%)        99 (48.3%)                                                   18 (69.2%)   36 (43.9%)                         26 (56.5%)   63 (51.2%)    
  **Cell differentiation**                                                                                                                                                             
  Well/ Moderately           65 (90.3%)        181 (88.3%)                    *p* = 0.646                   20 (76.9%)   67 (81.7%)   *p* = 0.591           45 (97.8%)   114 (92.7%)   *p* = 0.207
  Poorly                     7 (9.7%)          24 (11.7%)                                                   6 (23.1%)    15 (18.3%)                         1 (2.2%)     9 (7.3%)      

^a^ OR (95% CI):0.348 (0.136--0.891).

ijerph-17-05694-t004_Table 4

###### 

Clinicopathologic characteristics of lung adenocarcinoma patients with *EGFR* mutation, stratified by polymorphic genotypes of *FGFR4* rs351855.

  Variable                   ALL (*n* = 277)   *EGFR* Wild-Type (*n* = 108)   *EGFR* Mutation (*n* = 169)                                                                              
  -------------------------- ----------------- ------------------------------ ----------------------------- ------------ ------------ --------------------- ------------ ------------- -------------
  **Stages**                                                                                                                                                                           
  I + II                     19 (25.0%)        54 (26.9%)                     *p* = 0.753                   5 (17.9%)    21 (26.2%)   *p* = 0.371           14 (29.2%)   33 (27.3%)    *p* = 0.804
  III + IV                   57 (75.0%)        151 (73.1%)                                                  23 (82.1%)   59 (73.8%)                         34 (70.8%)   88 (72.7%)    
  **Tumor T status**                                                                                                                                                                   
  T1 + T2                    41 (53.9%)        127 (63.2%)                    *p* = 0.160                   12 (42.9%)   48 (60.0%)   *p* = 0.116           29 (60.4%)   79 (65.3%)    *p* = 0.552
  T3 + T4                    35 (46.1%)        74 (36.8%)                                                   16 (57.1%)   32 (40.0%)                         19 (39.6%)   42 (34.7%)    
  **Lymph node status**                                                                                                                                                                
  Negative                   23 (30.3%)        59 (29.4%)                     *p* = 0.882                   6 (21.4%)    22 (27.5%)   *p* = 0.528           17 (35.4%)   37 (30.6%)    *p* = 0.543
  Positive                   53 (69.7%)        142 (70.6%)                                                  22 (78.6%)   58 (72.5%)                         31 (64.6%)   84 (69.4%)    
  **Distant metastasis**                                                                                                                                                               
  Negative                   28 (38.9%)        106 (52.7%)                    ***p* = 0.018 ^a^**           8 (28.6%)    46 (57.5%)   ***p* = 0.008 ^b^**   20 (41.7%)   60 (49.6%)    *p* = 0.352
  Positive                   48 (63.2%)        99 (47.3%)                                                   20 (71.4%)   34 (42.5%)                         28 (58.3%)   61 (50.4%)    
  **Cell differentiation**                                                                                                                                                             
  Well/Moderately            69 (90.8%)        181 (88.1%)                    *p* = 0.520                   22 (78.6%)   65 (81.2%)   *p* = 0.758           47 (97.9%)   112 (92.6%)   *p* = 0.183
  Poorly                     7 (9.2%)          24 (11.9%)                                                   6 (21.4%)    15 (18.8%)                         1 (2.1%)     9 (7.4%)      

^a^ OR (95% CI):0.523 (0.304--0.899); ^b^ OR (95% CI):0.296 (0.116--0.751).

[^1]: These authors contributed equally to the work.
